Skip to Main Content

Author Details

Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
2010
98
41
PMIDPaper TitleJournal TitlePublished Year
37751743Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy.Cell Chem Biol2024
36928661Excessive transcription-replication conflicts are a vulnerability of BRCA1-mutant cancers.Nucleic Acids Res2023
37961351ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers.bioRxiv2023
38066556DNA methylation modulated genetic variant effect on gene transcriptional regulation.Genome Biol2023
37549269SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.Proc Natl Acad Sci U S A2023
37478850Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.Cancer Cell2023
37478845A lncRNA from the FTO locus acts as a suppressor of the m<sup>6</sup>A writer complex and p53 tumor suppression signaling.Mol Cell2023
37694973Transposable Elements Are Co-opted as Oncogenic Regulatory Elements by Lineage-Specific Transcription Factors in Prostate Cancer.Cancer Discov2023
37692852Genome-wide studies in prostate cancer poised liquid biopsy as a molecular discovery tool.Front Oncol2023
37402621MEDIPIPE: an automated and comprehensive pipeline for cfMeDIP-seq data quality control and analysis.Bioinformatics2023
37169182ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Immunotherapy.Gastroenterology2023
36997534MYC reshapes CTCF-mediated chromatin architecture in prostate cancer.Nat Commun2023
36877164LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.Cancer Res2023
36610996A polygenic two-hit hypothesis for prostate cancer.J Natl Cancer Inst2023
34511601TRIM21 regulates pyroptotic cell death by promoting Gasdermin D oligomerization.Cell Death Differ2022
36309516The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors.Nat Commun2022
36129942CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer.Proc Natl Acad Sci U S A2022
36251389The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer Res2022
35154288The Basis and Promise of Programmable RNA Editing and Modification.Front Genet2022
35181738Neonatal LTβR signaling is required for the accumulation of eosinophils in the inflamed adult mesenteric lymph node.Mucosal Immunol2022
34975152RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition.Oncogene2022
35121110Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer.Mol Ther2022
34968454N6-Methyladenosine Reader YTHDF1 Promotes ARHGEF2 Translation and RhoA Signaling in Colorectal Cancer.Gastroenterology2022
32946061Pioneer of prostate cancer: past, present and the future of FOXA1.Protein Cell2021
33851458Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge.Hepatology2021
33741908CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer.Nat Commun2021
33542074Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies.Clin Cancer Res2021
33822841Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy.J Exp Med2021
33899001EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.Nat Cancer2021
34911936Androgen receptor and MYC equilibration centralizes on developmental super-enhancer.Nat Commun2021
34615997ZNF545 loss promotes ribosome biogenesis and protein translation to initiate colorectal tumorigenesis in mice.Oncogene2021
34588438SPOP mutation induces DNA methylation via stabilizing GLP/G9a.Nat Commun2021
34489572An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.Nat Cell Biol2021
34716314Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse.Nat Commun2021
34621019CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer.Oncogene2021
34075878HNRNPM controls circRNA biogenesis and splicing fidelity to sustain cancer cell fitness.Elife2021
34168051Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma.Clin Cancer Res2021
33217448RNA N<sup>6</sup>-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m<sup>6</sup>A-GLUT1-mTORC1 Axis and Is a Therapeutic Target.Gastroenterology2021
33420488Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression.Nat Cell Biol2021
33270841CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy.Blood2021
33417860Colorectal Cancer Cells Enter a Diapause-like DTP State to Survive Chemotherapy.Cell2021
32203133Hypercholesterolemia risk-associated GPR146 is an orphan G-protein coupled receptor that regulates blood cholesterol levels in humans and mice.Cell Res2020
31662330MAP9 Loss Triggers Chromosomal Instability, Initiates Colorectal Tumorigenesis, and Is Associated with Poor Survival of Patients with Colorectal Cancer.Clin Cancer Res2020
31974375Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.Nat Commun2020
32714761Structural Basis of Human Helicase DDX21 in RNA Binding, Unwinding, and Antiviral Signal Activation.Adv Sci (Weinh)2020
32938917Haploinsufficiency of RREB1 causes a Noonan-like RASopathy via epigenetic reprogramming of RAS-MAPK pathway genes.Nat Commun2020
32868907Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer.Nat Genet2020
30655535ONECUT2 is a driver of neuroendocrine prostate cancer.Nat Commun2019
31844668Gastrointestinal transcription factors drive lineage-specific developmental programs in organ specification and cancer.Sci Adv2019
31862865Early-life programming of mesenteric lymph node stromal cell identity by the lymphotoxin pathway regulates adult mucosal immunity.Sci Immunol2019
  • 1 - 50 of 98

Recommended Authors

University of Texas Southwestern Medical Center at Dallas
Career Start Year 2017
Number of shared co-authors 9
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 25
Oncology R&D
Career Start Year 2013
Number of shared co-authors 26
Universitat Pompeu Fabra
Career Start Year 2012
Number of shared co-authors 16
University of British Columbia
Career Start Year 2011
Number of shared co-authors 37
McDermott Center for Human Growth and Development.
Career Start Year 2010
Number of shared co-authors 6
Keck School of Medicine of USC
Career Start Year 2009
Number of shared co-authors 8
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 63
University of Trento
Career Start Year 2008
Number of shared co-authors 15
UT Southwestern Medical Center
Career Start Year 2008
Number of shared co-authors 8
Northwestern University Feinberg School of Medicine Chicago
Career Start Year 2008
Number of shared co-authors 28
Dana-Farber Cancer Institute
Career Start Year 2006
Number of shared co-authors 14
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 2
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 43
The National Institutes of Health
Career Start Year 2006
Number of shared co-authors 2
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 9
University of Cambridge
Career Start Year 2003
Number of shared co-authors 15
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 5
Present address: Dxige Research Inc.
Career Start Year 2003
Number of shared co-authors 10
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 36
Meyer Cancer Center
Career Start Year 2001
Number of shared co-authors 20
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 16
Institute for Medical Research Israel-Canada, The Hebrew University of Jerusalem
Career Start Year 2000
Number of shared co-authors 6
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 20
Institute for Translational Epigenetics, University of Cologne
Career Start Year 1999
Number of shared co-authors 2
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 32
University of British Columbia
Career Start Year 1998
Number of shared co-authors 38
Queen's University Belfast
Career Start Year 1997
Number of shared co-authors 32
Case Western Reserve University School of Medicine
Career Start Year 1995
Number of shared co-authors 9
Center for Personal Dynamic Regulomes, Stanford University
Career Start Year 1992
Number of shared co-authors 7

Collaborators

Princess Margaret Cancer Centre, University Health Network
Co-authored papers 26
Princess Margaret Cancer Center/University Health Network
Co-authored papers 23
Co-authored papers 21
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 20
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 18
Co-authored papers 18
the Second Hospital, Cheeloo College of Medicine, Shandong University
Co-authored papers 15
School of Public Health, Sun Yat-sen University
Co-authored papers 14
Beth Israel Deaconess Medical Center and Harvard Medical School
Co-authored papers 14
University of California los angeles
Co-authored papers 14
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 13
UCSF Medical Center-Mount Zion
Co-authored papers 13
College of Life Science, Hunan Normal University
Co-authored papers 12
University Health Network, University of Toronto
Co-authored papers 12
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 11
Princess Margaret Cancer Research Centre
Co-authored papers 11
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 10
University of British Columbia
Co-authored papers 10
Co-authored papers 9
University of Toronto
Co-authored papers 9
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 8
University of British Columbia
Co-authored papers 7
Princess Margaret Cancer Research Centre
Co-authored papers 6
University of California los angeles
Co-authored papers 6
University of California los angeles
Co-authored papers 5
Dana-Farber Cancer Institute
Co-authored papers 5
Ontario Institute for Cancer Research
Co-authored papers 5
University of California-San Francisco
Co-authored papers 5
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 5
Dana-Farber Cancer Institute
Co-authored papers 5